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ABSTRACT 
Aspirin  and  the  other non steroidal  anti-inflammatory drugs  (NSAIDs)  are among  the most  often 
prescribed medicines. Co-administration of aspirin and NSAIDs is also common especially among 
patients  suffering  from  arthritis  and  cardiovascular  disease.  An  interaction  between  aspirin  and 
NSAIDs could affect both the antiplatelet effect of aspirin  and the safety of these agents in case of 
co-administration. For example, co-administration of aspirin with another NSAID could produce a 
pharmacodynamic interaction with subsequent enhancement or inhibition of antiplatelet effect of 
aspirin.  On the other hand, such a pharmacodynamic interaction could result in increased incidence 
of gastrointestinal and non gastrointestinal haemorrhage. This review aimed to summarize available 
data  on  the  possible  pharmacodynamic  interaction  between  aspirin  and  NSAIDs  and  the  clinical 
consequences of such an interaction.  Databases were searched electronically for relevant trials. 
Identified  data  were  quite  limited.  Theoretically  at  the  molecular  level,  a  competitive  interaction 
between  aspirin  and  NSAIDs  could  be  anticipated  in  case  of  prior  administration  of  a  NSAID. 
However, in vitro data indicate that concurrent administration of aspirin and diclofenac potentiates 
the inhibition of platelet aggregation. Yet, in vivo studies have failed to prove competitive interaction 
between aspirin and diclofenac in platelet aggregation, or suggest minimal effect of diclofenac on 
platelet aggregation, when administered concurrently with aspirin. Retrospective studies based on 
prescription databases have suggested that ibuprofen counteracts the antiplatelet effect of aspirin. 
There is limited evidence on how NSAIDs affect platelet aggregation in vivo when they are given 
together with aspirin according to a regular clinical schedule e.g. a morning dose of aspirin and 
repeated doses of NSAIDs during the day. Existing data suggest an interaction between aspirin and 
NSAIDs on haemostasis. However, there is controversy regarding the direction of this interaction, 
i..e. synergism or antagonism. Since, co-administration of aspirin and NSAIDs is quite common in 
people  with  comorbidities,  further  research  is  needed  to  clarify  the  clinical  significance  of  this 
interaction. 
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[I] INTRODUCTION  
 
Aspirin and the other non steroidal anti-inflammatory drugs 
(NSAIDs)  are  among  the  most  often  prescribed  medicines. 
Co-administration  of  aspirin  and  NSAIDs  is  also  common 
especially  among  patients  suffering  from  arthritis  and 
cardiovascular disease. Daily doses of 75-125 mg of aspirin 
are  recommended  for  individuals  at  high  risk  for 
cardiovascular  disease.  When  drugs  with  similar 
pharmacologic  effects  are  administered  concurrently,  an 
additive  or  synergistic  interaction  is  usually  seen.  An 
antagonistic interaction is also possible, but not common. On 
the other hand the combined use of two or more drugs, each of 
which has toxic effects on the same organ can greatly increase 
the  possibility  of  such  an  organ  damage.  An  interaction 
between aspirin and NSAIDs could affect both the antiplatelet 
effect of aspirin and the safety of these agents in case of co-
administration.  
 
For  example,  co-administration  of  aspirin  with  another 
NSAID  could  produce  a  pharmacodynamic  interaction  with 
subsequent enhancement or inhibition of antiplatelet effect of The IIOAB Journal 
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aspirin  [1].  On  the  other  hand,  such  a  pharmacodynamic 
interaction  could  result  in  increased  incidence  of 
gastrointestinal and non gastrointestinal haemorrhage [1]. The 
possibility, mechanisms and clinical significance of such an 
interaction have not been fully investigated. This study aimed 
to review the possible pharmacodynamic interaction between 
aspirin and NSAIDs and the clinical consequences of such an 
interaction.  
 
 
[II] CO-ADMINISTRATION OF NSAIDS AND 
LOW DOSE ASPIRIN 
 
Data were quite limited.  A few randomized controlled trials 
were identified and all of them included a small number of 
healthy  volunteers.  Catella-Lawson  et  al.[2]  performed  a 
randomized cross over study with single doses of aspirin and 
ibuprofen and a parallel group study with multiple doses of 
aspirin  and  ibuprofen.  Serum  thromboxane  B2  levels    (an 
index of cyclo-oxygenase I activity in platelets) and  platelet 
aggregation were maximally inhibited 24 hours after aspirin in 
the patients who took aspirin before any dose of any single 
drug, as well as in those who took rofecoxib or acetaminophen 
before aspirin. In contrast, in subjects who took 400 mg of 
ibuprofen  two  hours  before  taking  81  mg  of  aspirin, 
thromboxane B2 formation was inhibited by only 53% on day 
7. The authors concluded that co-administration of NSAIDs 
with  aspirin  may  interfere  with  the  irreversible  antiplatelet 
function  of  aspirin  resulting  thus  in  attenuation  of  the 
antiplatelet effect [2].  
 
Another  RCT,  that      included  eleven  healthy  volunteers, 
investigated the influence of co-administration of aspirin with 
diclophenac,  naproxen  and  acetaminophen  on  platelet 
aggregation.  They  demonstrated,    that  co-administration  of 
aspirin with NSAIDs may interfere with platelet aggregation 
at the beginning of the treatment,  with  naproxen  having  an 
additional anti-aggregatory effect to that brought by a single 
dose  of  100  mg  aspirin  and  with  diclofenac  decreasing  the 
antiagregatory  effect  of  aspirin.  The  effect  was  lost  after  4 
days  and  the  authors  concluded  that  a  regular  daily 
administration of NSAID does not have an effect on platelet 
aggregation  [3].  Capone  et  al.[4]  investigated  the 
pharmacodynamic  interaction  of  naproxen  with  low  dose 
aspirin  in  four  healthy  volunteers,  who  received  aspirin 
(100mg  per  day)  for  six  days  and  then  the  combination  of 
aspirin and naproxen for further six days, aspirin two hours 
before naproxen (500 mg twice daily) . Following a washout 
period  of  14  days,  naproxen  was  given  before  aspirin  for 
further  six  days.  Ex  vivo  markers  of  platelet  function  were 
measured. Co-administration of naproxen did not significantly 
alter the antiplatelet action of aspirin.  
 
On the contrary, in the study of Gladding et al.[5], ibuprofen, 
indomethacin,  naproxen  and  tiaprofenic  acid  blocked  the 
antiplatelet effect of aspirin. Gengo et al.[6] investigated the 
interaction  of  ibuprofen  and  low  dose  aspirin  in  healthy 
volunteers and the interaction of ibuprofen or naproxen with 
aspirin in a confirmatory study of 28 patients taking low dose 
aspirin  for  stroke  prevention.    The  data  of  both  studies 
suggested that ibuprofen prevented the irreversible inhibition 
of  platelet  aggregation  produced  by  low  dose  aspirin. 
However, it seems that the type of interaction between aspirin 
and NSAIDs may differ among different NSAIDs. Thus,  in 
vivo  studies  have  failed  to  prove  competitive  interaction 
between  aspirin  and  diclofenac  in  platelet  aggregation,  or  
suggest minimal effect of diclofenac on platelet aggregation, 
when  administered  concurrently  with  aspirin  [7,8]. 
Observational studies  have conflicting results.  Retrospective 
studies  suggest  that  ibuprofen  counteracts  the  antiplatelet 
effect of aspirin [9,10]. However, the strength of evidence is 
limited, since data came from prescription databases.  
 
 
[III] MECHANISM OF PHARMACODYNAMIC 
INTERACTION 
 
The most predicted hematological adverse reaction of aspirin 
and NSAIDs is due to inhibition of cyclo-oxygenase  I. COX-I 
catalyzes the transformation of membrane bound arachidonic 
acid  to  thromboxane  A2,  a  platelet  agonist    with  resultant 
reduced  platelet  adhesiveness  and  prolongation  of  bleeding 
time.  According  to  crystallographic  data,  aspirin  inhibits 
cyclo-oxygenase by irreversible acetylation of a serine residue 
in vicinity with the catalytic site of the enzyme, while NSAIDs 
bind to the same hydrophobic channel of COX I in the vicinity 
of aspirin [11,12].  
 
Because  the  ability  of  aspirin  to  acetylate  a  critical  serine 
residue at the apex of the COX channel is dependent on its 
initial binding to arginine-120,
 a common docking site for all 
NSAIDs, the stronger binding affinity of nonaspirin NSAIDs 
might preclude aspirin from  permanently  modifying platelet 
COX-1. Thus, theoretically in molecular level, a competitive 
interaction between aspirin and NSAIDs could be anticipated 
in case of prior administration of a NSAID. On the other hand, 
highly selective COX-2 inhibitors (coxibs) are less likely to 
interfere  with  the  antiplatelet  effect  of  aspirin  than 
conventional NSAIDs because of their limited interaction with 
platelet COX-1.  
 
However, in cellular and organism level, synergistic or even 
additive effect between aspirin that irreversibly blocks COXI 
activity and diclofenac that reversibly blocks COXI activity 
could  be  anticipated.  First  of  all,  low  doses  of  aspirin  are 
associated with high inhibition of COXI as demonstrated by 
almost total inhibition of serum thromboxane [13]. However, 
there  is  residual  platelet  reactivity  in  patients  treated  with 
aspirin,  the  antiplatelet  action  of  aspirin  seems  to  be  dose-
related, implying  thus, that aspirin as an antiplatelet might 
affect other targets besides COXI [14]. For example, reactive 
oxygen species seem to play a significant role in the regulation 
30  The IIOAB Journal 
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of  platelet  activation  [15].  Aspirin  has  been  shown  to 
modulate reactive oxygen species through its pro-oxidant or 
antioxidant actions [16]. Additionally, aspirin has been shown 
to  enhance  fibrinolysis  and  suppress  plasma  coagulation, 
although the clinical significance of these is not determined.  
There  is  limited  evidence  on  how  NSAIDs  affect  platelet 
aggregation in vivo when they are given together with aspirin 
according to a regular clinical schedule e.g. a morning dose of 
aspirin and repeated doses of NSAIDs during the day. 
  
[IV] NSAIDS AND ANTIPLATELET ACTION 
 
The antiplatelet action of NSAIDs is a matter of controversy. 
It  has  been  demonstrated  that  NSAIDs  have  in  vitro 
antiplatelet  action.  However,  in  ex  vivo  studies,  there  is 
extensive variability on the extent and duration of the effects 
of NSAIDs on platelet aggregation and on bleeding times. The 
antiplatelet  effects  of  long  acting  NSAIDs  like  piroxicam 
persist  for  several  days  after  the  drug  is  stopped.  Platelet 
aggregation is inhibited within 2 hours after a single dose of 
ibuprofen, but the effect is lost within 12 hours. High dosages 
of  ibuprofen  cause  slight  but  significant  prolongations  of 
bleeding time for several hours while lower doses (e.g. 200 
mg  three  times  daily)  may  not  affect  the  bleeding  time.  In 
general,  most  NSAIDs  cause  transient  dose  dependent 
prolongations of bleeding time, without exceeding the upper 
limit of normal range for bleeding time [17]. 
 
The clinical significance of the antiplatelet action of NSAIDs 
is  not  determined  [18-20].  Clinical  trials  have  suggested 
cardioprotective  effect  of  naproxen,  flurbiprofen  and 
diclofenac due to antiplatelet action [21-24]. However, other 
papers imply that NSAIDs do not have an antiplatelet action, 
since:  first,  the  relation  between  the  inhibition  of  platelet 
cyclo-oxygenase I dependent thromboxane A2 generation and 
the inhibition of thromboxane dependent platelet function is 
non  linear  and  second,  NSAIDs  inhibit  platelet  cyclo-
oxygenase  I,  but  the  inhibition  lasts  for  only  a  part  of  the 
dosing interval. It has been proposed that platelet COX-I has 
to be almost completely (>95%) and continuously inhibited ex 
vivo throughout the dosing intervals to translate to a detectable 
cardiovascular protection. However, an antiplatelet action has 
been  proposed  for  naproxen.  It  has  been  suggested  that 
naproxen  inhibits  platelet  cyclo-oxygenase  I  for  the  whole 
duration of the dosing interval.  Ex vivo studies have shown 
that naproxen at therapeutic doses of 500 mg twice daily gets 
into  the  functionally  relevant  range  of  inhibition  of  platelet 
COX I activity (>95%), at the end of the dosing interval in 
some  subjects  [25].  Additionally,  NSAIDs  might  affect 
platelet  function  in  a  cyclo-oxygenase  independent 
mechanism.  A  recent  paper  suggests  antagonism  of 
thromboxane  receptors  as  a  novel  mechanism  of  action  of 
diclofenac [26].  Therefore, it could be proposed that COXI 
independent  mechanisms  might  contribute  to  the 
pharmacodynamic interaction between aspirin and diclofenac 
on hemostasis. 
[V]  CLINICAL  SIGNIFICANCE  OF  NSAIDs–
ASPIRIN INTERACTION 
 
The possible interaction of aspirin and NSAIDs on antiplatelet 
action is clinically significant not only in cardioprotection but 
also  in  aspirin  and  NSAIDs  induced  haemorrhage.  If  co-
administration  of  aspirin  and  NSAIDs  enhances  antiplatelet 
action of aspirin alone, increased frequency of gastrenteric and 
non gastrenteric hemorrhage is expected. Indeed, intracerebral 
hemorrhage  is  the  most  serious  spontaneous  hemorrhage 
caused by aspirin. It seems that patients prescribed non aspirin 
NSAIDs  are  not  at  an  overall  increased  risk  of  being 
hospitalized for intracerebral hemorrhage. However, existing 
data are quite scarce, and there is no estimation about the risk 
in case of co-administration of aspirin and NSAIDs [27].  
 
[VI] CONCLUSION 
 
Existing  data  suggest  an  interaction  between  aspirin  and 
NSAIDs  on  haemostasis.  However,  there  is  controversy 
regarding the direction of this interaction, i..e. synergism or 
antagonism. Since, co-administration of aspirin and NSAIDs 
is quite common in people with comorbidities, further research 
is needed to clarify the clinical significance of this interaction. 
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